The authors reply

We thank Sheng-Wen Niu and colleagues1 for highlighting their intriguing data on the association between pioglitazone use and incident nephrolithiasis in patients with type 2 diabetes in the Taiwanese National Health Insurance Research Database. In their population-based retrospective analysis, pioglitazone users experienced a 26% reduction in kidney stone incidence compared with matched diabetic nonpioglitazone users, and greater risk reduction was observed with higher cumulative pioglitazone exposure.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Letter to the Editor Source Type: research